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Abstract 
 
There is growing interest in the re-emerging interaction between type 2 diabetes (DM) and 
tuberculosis (TB), but the underlying biological mechanisms are poorly understood despite 
their possible implications in clinical management. Experts in epidemiological, public health, 
basic science and clinical studies recently convened and identified research priorities for 
elucidating the underlying mechanisms for the co-ocurrence of TB and DM. We identified 
gaps in current knowlege of altered immunity in DM patients during TB, where most studies 
suggest an under-performing innate immunity, but exaggerated adaptive immunity to 
Mycobacterium tuberculosis. Various molecular mechanisms and pathways that may 
underly these observations in the DM host. These include signaling induced by excess 
advanced glycation end products (AGE) and their receptor (RAGE), higher levels of reactive 
oxidative species and oxidative stress, epigenetic changes due to chronic hyperglycemia, 
altered nuclear receptors and/or differences in cell metabolism (immuno-metabolism). 
Studies in humans at different stages of DM (no DM, pre-DM and DM) or TB (latent or active 
TB) should be complemented with findings in animal models, which provide the unique 
opportunity to study early events in the host-pathogen interaction. Such studies could also 
help identify biomarkers that will complement clinical studies in order to tailor the 
prevention of TB-DM, or avoid the adverse TB treatment outcomes that are more likely in 
these patients. Such studies will also inform new approaches to host-directed therapies.  
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Summary box  
 
• Type 2 diabetes is a syndrome characterised by a range of metabolic (e.g. 
hyperglycemia, hyperlipidemia), inflammatory, vascular and other changes that 
may all contribute to increasing TB susceptibility and pathology.  
• Monocytes and macrophages from diabetic patients and mice have defects leading 
to altered interactions with M. tuberculosis and delayed adaptive immune 
responses. 
• Most human studies have been conducted in patients with active TB, where those 
with TB-DM comorbidity are characterised by increased secretion of Th1, Th17 and 
Th2 cytokines. However, the few studies in individuals at risk for TB (LTBI) suggest 
a different cytokine profile. 
• Molecular pathways that involve AGE/RAGE, ROS, nuclear receptors and cellular 
metabolism are potential  targets for host-directed therapies to reduce TB 
susceptibility or pathology in DM patients.   
• Animal models for TB-DM can improve our understanding of underlying 
mechanisms and effective treatment approaches for the comorbidity of TB and 
DM.  
 
Introduction 
Type 2 diabetes mellitus (DM) increases the risk of many infectious diseases, including 
tuberculosis
1
 (TB), and it is now recognized that the increasing DM prevalence in high TB 
incidence countries such as Sub-Saharan Africa (SSA) is a challenge to TB control.
2
 The 
known association between a chronic syndome like DM and an infectious disease like TB 
requires the near term development of a comprehensive research agenda that effectively 
integrates the basic sciences with clinical decision making and policy to reduce the impact of 
the co-morbidity. To address this research agenda, a group of international TB and DM 
experts convened at the National Institutes of Health (NIH) in May 2016 to discuss the 
convergent epidemics of DM and TB along with HIV. In this Part 2, we summarize the 
biological mechanisms that were identified as research priorities. 
 
Knowledge of the altered biological mechanisms and pathways associated with TB and DM 
is needed to help identify the subgroup of DM patients at highest risk of progression to TB. 
This knowledge will also benefit DM patients with a new diagnosis of TB will require 
modifications in the standard TB treatment schedule in order to prevent adverse treatment 
outcomes. It is increasingly clear that although TB and DM have different pathogenic 
mechanisms, they also  share a number of similarities at the molecular level, including key 
pathways involved in chronic inflammation, metabolism and immunity.
3-5
 It is critical to gain 
insight into the factors underlying the links between TB and DM at the molecular, cellular 
and systemic levels and to integrate data from clinical studies and animal models to better 
understand the fundamental causes and consequences of the comorbidity.  
 
Altered immunity: The effect of pre-DM and DM on human immunity to M. tuberculosis 
during TB and LTBI  
Recent reviews have addressed the effect of DM on host response to M. tuberculosis
4,6,7
. 
Studies on human innate immune responses indicate that monocytes from poorly-
controlled DM patients (versus well-controlled or non-DM) have significantly lower binding 
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and phagocytosis of M. tuberculosis, and this defect is attributable to alterations in the 
diabetic monocyte as well as in serum opsonins
8-10
. Efficient phagocytosis and proper 
adaptive immune priming are necessary to activate cell-mediated immune responses that 
restrict M. tuberculosis growth, and delayed or altered responses likely contribute to 
diabetic TB susceptiblity
11
. Diabetic individuals with LTBI have lower frequencies of  M. 
tuberculosis-specific pro-inflammatory (Th1 and Th17), anti-inflammatory (IL-10) and Th2 
responses compared to normoglycemic individuals with LTBI
12,13
.  The IL-20 family of 
cytokines is also lower in LTBI-DM whereas IL-22 is higher
14
. Once patients have developed 
active TB disease, those with DM exhibit higher circulating levels of Th1 and Th17 (except 
for IL-22) cytokines as well as higher frequencies of lymphocytes (CD4+, CD8+) and NK cells 
expressing these cytokines in response to M. tuberculosis antigens
15-19
. However, TB-DM 
patients also have higher levels of anti-inflammatory cytokines, notably IL-10
16
. The higher 
expression of pro-inflammatory cytokines could reflect higher bacillary load in TB-DM, as a 
consequence of a delayed initial control of M. tuberculosis replication (along with increased 
tissue damage) as a consequence of weak cytokine responses to LTBI in humans. Other 
contributing factors may be a reduced frequency of natural regulatory T cells in TB-DM 
patients
17
 and hyper-responsiveness to T cell antigen receptor stimulation as identified in 
diabetic mice
20
. Nearly all studies on innate and adaptive immune responses in TB-naive, 
LTBI and TB patients have been conducted in peripheral blood cells. However, one study in 
TB-DM patients evaluated the lung environment, and showed higher IL-10 and lower IFN-γ 
in TB-DM, suggesting an anti-inflammatory bias in this compartment as well
21
.  
Few studies have focused on individuals with pre-DM (characterized by insulin resistance 
and pancreatic β-cell dysfunction prior to detectable changes in glycemic control) or 
intermediate hyperglycemia despite their high risk for future DM. Babu et al
12,22
 have 
focused on investigating the influence of pre-DM on antigen-stimulated cytokine production 
in active TB and LTBI. Individuals with pre-DM and active TB have increased circulating levels 
of Th1 (IFNγ, TNFα, IL2), Th2 (IL-4, IL-5), Th17 (IL-17A, IL-17F) and regulatory cytokines (IL-
10, TGFβ) compared to TB patients without pre-DM. However, IL-22 concentrations do not 
differ. Individuals with LTBI and pre-DM exhibited diminished circulating levels of Th1, Th2, 
Th17 and regulatory cyokines compared to normoglycemic participants with LTBI, as well as 
decreased M. tuberculosis antigen-stimulated cytokine concentrations.  
Together, studies on human immunity in TB-naive, LTBI or TB patients indicate dysfunctional 
immunity in pre-DM and DM patients that calls for further studies. The mechanisms and 
impact of the defects observed on M. tuberculosis growth containment as well as immune 
pathology are incompletely understood. Furthermore, there is a paucity of studies 
evaluating the lung, which is the primary site of TB disease, and the relationship between 
the immune responses to M. tuberculosis in the lung and periphery is poorly understood. 
Given the higher prevalence of pulmonary (versus extrapulmonary) TB among DM 
patients,understanding this compartmentalization is particularly relevant
4,23
. Data from the 
mouse TB-DM model suggest that chronic hyperglycemia exerts unique effects on alveolar 
versus peritonal and bone marrow-derived macrophages
24
. Thus, integration of the 
observed immunometabolic abnormalities in pre-diabetic and diabetic hosts warrant futher 
investigation. 
Advanced glycation end products and RAGE signaling  
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Advanced glycation end products (AGEs) accumulate during metabolic disorders fueled by 
hyperglycaemia. The receptor for AGEs, RAGE, is expressed on a variety of cell types 
including those highly relevant in the context of TB and DM (e.g., monocytes and 
macrophages, dendritic cells, T-cells and vascular cells).  Interestingly, the highest 
expression of RAGE occurs in the lungs
25
, the primary site of M. tuberculosis infection. 
Activation of RAGE up-regulates inflammation through the production of reactive oxigen 
species (ROS) and inflammatory cytokines, and alters phagocytosis and cellular lipid 
metabolism.  
At the present time, there are no approved drugs that target AGEs or RAGE in the treatment 
of DM and diabetic complications. However, a new class of 2-aminoimidazole-based small 
molecules have been shown to have potent anti-AGE activity in vitro
26
. Inhibition  or 
blocking the pro-inflammatory response as a consequence of AGE-RAGE interactions may 
prove to be an effective adjunctive therapy in the treatment of TB-DM comorbity. 
 
ROS as a central mediator   
In the host defence against mycobacteria, ROS regulates cytokine production, autophagy 
and granuloma formation
27
, but excessive ROS production leads to impaired cellular 
function and pathology. Hyperglycemia- and free fatty acid-induced overproduction of ROS 
activates the major pathways of diabetic cellular damage. Furthermore, hyperglycemia-
induced ROS production leads to histone modifications in the NFkB p65 proximal promoter 
resulting in gene activation of this major regulator of inflammatory genes
28
. Although 
increased mitochondrial ROS production enhances mycobacterial killing in macrophages, 
increased ROS production can also increase necroptosis and mycobacterial release into the 
extracellular milieu
29,30
. Therefore, DM metabolite-induced increased ROS production may 
further contribute to the increased rate of relapse  and death in TB patients with poor 
glycemic control. The diabetic phenotypes of alveolar macrophage recognition of M. 
tuberculosis and T cell hyper-responsiveness were also shown to be at least partially 
dependent on RAGE expression
57, 24
. Thus, blocking the RAGE signaling pathway may reduce 
ROS generation and may prove useful in the context of TB-DM comorbidity. 
 
Nuclear receptors  
Another potential family of therapeutic targets and key molecular players in metabolic and 
immunological pathways are nuclear receptors (NRs). Peroxisome proliferator-activated 
receptors (PPARs) are highly expressed in a variety of tissues including adipose tissue, 
macrophages and dendritic cells and play a major role in lipid metabolism, but also in innate 
and adaptive immunity. PPARγ is of particular interest as it is also highly expressed in 
alveolar macrophages, where it contributes to the formation of foam cells and promotes 
anti-inflammatory gene expression while transrepressing pro-inflammatory gene expression 
upon ligand binding
31
; it also serves as a biological marker for alternatively activated 
macrophages (M2 phenotype)
32
. M. tuberculosis infection of macrophages induces PPARγ 
via the mannose receptor (MR, CD206)
33
 and TLR2
34
 and in turn increases M. tuberculosis 
intracellular growth, lipid body formation and chemokine release. PPARγ knock down 
followed by M. tuberculosis infection leads to decreased growth, and an increase in 
expression of 36 genes (including BAX) and a decrease in expression of 31 genes. Therefore, 
it is possible that activation of PPARγ by M. tuberculosis limits cellular apoptosis by 
inhibiting BAX expression and inducing Mcl-1 (Arnett and Schlesinger, unpublished). One 
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could envision that PPARγ antagonists could potentially be used to prevent primary TB 
infection, whereas PPARγ agonists (which are used in the treatment of DM) could have a 
beneficial effect as an adjunct host-directed therapy to reduce inflammation during active 
TB disease. 
 
Altered host metabolism in tuberculosis 
It has recently been shown that M. tuberculosis induces a switch in host cellular metabolism 
towards aerobic glycolysis in humans. The metabolic switch is TLR2-dependent but NOD2-
independent, and is mediated in part through activation of the AKT-mTOR pathway
35
. 
Pharmacological inhibition of the AKT/mTOR pathway inhibits cellular responses to M. 
tuberculosis both in vitro and in vivo in a model of murine TB. Another study showed how 
responses to BCG depend on changes in cellular metabolism and epigenetics.
36
 These 
findings reveal a novel regulatory layer of host responses to M. tuberculosis that could be 
exploited for host-directed therapy. Indeed, the antidiabetic drug metformin, which inhibits 
mTOR through induction of AMPK (adenosine monophosphate–activated protein kinase), 
was shown to increase mitochondrial reactive oxygen species, facilitate phagosome-
lysosome fusion and reduce growth of M. tuberculosis in macrophages.
37
 In this same study, 
metformin ameliorated lung pathology, reduced chronic inflammation, and enhanced the 
specific immune response and efficacy of conventional TB drugs in M. tuberculosis-infected 
mice. Similarly, metformin treatment in the guinea pig model of TB restored systemic 
glucose metabolism and lessened pulmonary pathology (Basaraba and Podell unpublished). 
This work should be extended, also evaluating effects of other antidiabetic drugs, to 
establish the role of cellular metabolism in TB-DM.  
 
Mouse models to study TB-DM comorbidity 
In TB-DM mouse models, susceptibility to TB is observed with chronic but not acute 
hyperglycemia.
38,39
 Chronic hyperglycemia in mice impairs the innate response of resident 
alveolar macrophages to inhaled M. tuberculosis. The resulting delay in recruiting myeloid 
cells, including neutrophils and dendritic cells to the alveolar airspace, leads to a delay in 
transferring bacilli from the lung to the lymph node and a delay in priming the adaptive 
immune response
40
. Alveolar macrophages from diabetic mice have reduced CD14 and 
macrophage receptor with collagenous structure (MARCO) expression and display reduced 
phagocytosis
24
. Transfer of infected alveolar macrophages from diabetic mice into 
normoglycemic recipients confirmed an intrinsic defect that hinders T cell priming. This 
delay permits several additional days of logarithmic increase in lung bacterial load before 
antigen-specific T cells reach the lung and restrict bacterial replication. The phenotype of 
diabetic alveolar macrophages is not shared by macrophages from other compartments in 
diabetic mice, such as the peritoneal or bone marrow-derived macrophages of chronic 
hyperglycemic mice. This unique macrophage phenotype appears to be dependent in part 
on the expression of RAGE
24
. Once the immune response to M. tuberculosis is initiated in 
the DM mice, it is excessive. In a recent study, the interaction between NK and CD11c+ 
(dendritic cells) led to excessive IL-6 driven immune pathology in DM mice.
39
 Naive T cells in 
diabetic mice display chromatin decondensation similar to activated T cells. This chromatin 
decondensation is also RAGE dependent and persists upon adoptive transfer to a non-
diabetic host manifesting in increased expression of a broad range of cytokines and 
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increased proliferation of stimulated diabetic versus normoglycemic T cells
20
. Similar to 
diabetic mice, DM patients show increased immune pathology and increased expression of a 
broad range of Th1, Th2 and Th17 cytokines that could not otherwise be attributed to a 
perturbation of signal transduction through any one particular pathway.  
 
Overall, the mouse offers an informative approach to model the mechanisms of TB 
susceptibility in humans with DM. Furthermore, the alveolar macrophage phenotype of 
mice suggests that a major adverse effect of DM occurs months prior to the ususal timing of 
clinical TB diagnosis and might be mediated by epigenetic programming.  
 
Guinea pig models for DM and TB  
The guinea pig displays a similar pathology and metabolic response to M. tuberculosis 
infection as seen in humans. The guinea pig model utilized in co-morbidity studies by Podell 
and collegues
41
 closely replicates the pathogenesis of human type 2 DM, which is important 
since dyslipidemia, hyperinsulinemia and insulin resistance are all potential contributing 
factors in human diabetic immunopathy. Like diabetic guinea pigs, pre-diabetic guinea pigs 
had a higher pulmonary and extra-pulmonary bacterial burden and an increased expression 
of pro-inflammatory cytokines in the late stages of infection compared to non-diabetic 
animals. Compared to normal guinea pigs, IFN-γ, IL-17, TNF-α and IL-1β levels were elevated 
in the spleen. At day 30 post-infection in diabetic guinea pigs, the high lung and extra-
pulmonary M. tuberculosis burden was accompanied by a neutrophil-driven inflammatory 
response resulting in more severe granuloma necrosis. Despite elevated Th1 responses, 
guinea pigs were unable to contain bacterial growth and they display exacerbated 
immunopathology. Also similar to the mouse model, the delivery of viable bacteria to the 
lung-draining lymph nodes was delayed in guinea pigs due to a cellular defect where 
antigen-presenting cells in DM remain in a state of immaturity and have impaired capacity 
to migrate towards chemoattractant stimuli (Podell et al. unpublished). Diabetic guinea pigs 
had higher mortality during TB treatment than non-diabetic control animals or those with 
diet-induced impaired glucose tolerance, which corresponds to the increased TB mortality in 
human patients with TB-DM comorbidity. Taken together, the guinea pig model 
complements the mouse model and shares important similarities with the naturally occuring 
disease in humans and is an essential tool to better understand the underlying mechanisms 
of TB-DM comorbidity, as well as interrogate new therapeutic and preventative therapies. 
 
Future perspectives and research prioirities 
TB and DM have a complex interaction affecting a number of molecular pathways that we 
are just beginning to be understand. Knowledge of these pathways will directly impact the 
approaches we take to diagnosis, treatment and prevention. During the expert meeting 
some important conclusions and priority areas for further study were identified. 
First, different mechanisms may underly increases in TB susceptibility, early deaths, disease 
severity and TB recurrence in DM patients. It will be necessary to tease out specific 
epidemiological links and do careful phenotyping to select the most appropriate individuals 
for basic science studies. Such studies could also help identify biomarkers to direct 
treatment and foster basic research of the interaction of TB and DM. Phase II clinical trials 
should examine possible host-directed strategies. 
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Basic research should focus on immune-metabolic pathways and other molecular 
mechansims underlying defective anti-mycobacterial immune responses in DM, capitalizing 
on knowledge gained in the cancer field relating to drugs, drug targets and host signaling 
pathways that impact immunology and metabolism. The impact of DM on memory T cell 
expansion and lifespan is unexplored, as are the potential effects of DM on T cell 
senescence. Likewise, the mechanisms underlying aberrant pro-inflammatory signaling 
pathways in the innate immune system in DM need further exploration since they likely 
directly influence alterations in the developing adaptive immune response.  
Animal models offer opportunities to investigate early events in the host-pathogen 
interaction relevant to human TB-DM comorbidity that are not ammenable to clinical 
studies; mechanisms of TB-associated metaflammation in adipose tissue; and cost-effective 
models for preclinical studies of host-directed therapies. 
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